Study sites
Weill Cornell Medical Center | Cleveland Clinic | Hospital of the University of Pennsylvania
KONECT RESILIA aortic valved conduit
The first real-world multicenter study of bio-Bentall procedures with a novel pre-assembled aortic valved conduit1
Number of patients
329 patients
Aortic valve etiology
Aortic aneurysm, aortic dissection, endocarditis, and valvular dysfunction
Freedom from all-cause mortality at one year
Freedom from cardiovascular death at one year
Freedom from aortic valve or root reoperation at one year
Median overall CXT and isolated root CXT during surgery
The KONECT RESILIA aortic valved conduit offers a simplified approach to root replacement, with excellent short-term outcomes reported through one year.
Single-center retrospective study of adults undergoing elective bio-Bentall procedures with KONECT RESILIA aortic valved conduit2
Study site
Yale School of Medicine, Division of Cardiac Surgery
Number of patients
118 patients
Study years
2021-2023
Low operative and short-term mortality
Median length of stay: 6.5 days
Initial findings suggest the KONECT RESILIA aortic valved conduit may offer favorable early outcomes for patients undergoing aortic root and valve replacement.
RESILIA tissue data from the COMMENCE aortic trial show*
Proven performance at 7 years
Freedom from all-cause mortality through 7 years
Freedom from structural valve deterioration through 7 years
Clinically stable hemodynamics
*Clinical data on surgical valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up to 10-years in progress.3
KONECT RESILA aortic valved conduit publications
June 6, 2025
Early experience with a prefabricated bioprosthetic aortic valved conduit: the first hundred4
June 9, 2025
Propensity-matched analysis of mechanical vs bioprosthetic aortic root replacement: management of the dissected aortic root in young patients5
January, 2022
In-human case series highlights surgical advantages of KONECT RESILIA aortic valved conduit6
KONECT RESILIA aortic valved conduit
*As compared to self-assembled valved conduits
§As compard to self=assembled valved conduits with non-RESILIA valves
†Clinical data on valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up to 10-years in progress.
References
- Roselli E, Girardi L, Desai N, et al. First real-world multicenter series of bio-Bentall procedures with a novel pre-assembled aortic valved conduit. Podium presentation at: European Association for Cardio-thoracic Surgery; October 8-11 2025; Copenhagen, Denmark. Accessed October 09.2025.
- Erez E, Dankwa S, Higaki A, et al. Clinical, physiologic, and anatomic outcomes of a new bioprosthetic aortic valved conduit: 1-year outcomes. Presented at: 61st Annual Meeting of the Society of Thoracic Surgeons (STS 2025); January 26, 2025; Los Angeles, CA. Available at: https://sts2025.eventscribe.net/fsPopup.asp?PresenterID=1746287&mode=posterPresenterInfo
- Beaver T, Bavaria JE, Griffith B, et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. J Thorac Cardiovasc Surg. 2024;168(3):781-791. doi:10.1016/j.jtcvs.2023.09.047
- Calderon-Rojas R, Bagameri G, Schaff HV, et al. Early experience with a prefabricated bioprosthetic aortic valved conduit: The first 100. JTCVS Open. 2025;26:34-43. Published 2025 Jun 6. doi:10.1016/j.xjon.2025.04.024
- Catalano MA, Toubat O, Gillinov L, et al. Management of the dissected aortic root in young patients: A propensity score-matched analysis of mechanical versus bioprosthetic aortic root replacement. JTCVS Open. 2025;26:22-33. Published 2025 Jun 9. doi:10.1016/j.xjon.2025.05.009
- DeRoo SC, Desai N, Grimm JC, Cannon B, Bavaria JE. In-Human Implantation of a Novel Biologic ValvedConduit for Aortic Root Replacement. Ann Thorac Surg. 2022;113(1):e21-e24. doi:10.1016/j.athoracsur.2021.03.087
- Sadri V, Madukauwa-David ID, Yoganathan AP. In vitro evaluation of a new aortic valved conduit. J Thorac Cardiovasc Surg. 2021;161(2):581-590.e6. doi:10.1016/j.jtcvs.2019.09.181
Important Safety Information
Important Safety Information
KONECT RESILIA Aortic Valved Conduit
Indications: For use in replacement of native or prosthetic aortic heart valves and the associated repair or replacement of a damaged or diseased ascending aorta.
Contraindications: There are no known contraindications with the use of the KONECT RESILIA aortic valved conduit.
Complications and Side Effects: Thromboembolism, valve thrombosis, hemorrhage, hemolysis, regurgitation, endocarditis, structural valve deterioration, nonstructuraldysfunction, stenosis, arrhythmia, transient ischemic attack/stroke, congestive heart failure, myocardial infarction, any of which could lead to reoperation, explantation,permanent disability, and death. Adverse events potentially associated with the use of polyester vascular grafts include hemorrhage, thrombosis, graft infection, embolism,aneurysm, pseudoaneurysm, seroma, occlusion (anastomotic intimal hyperplasia), immunological reaction to collagen (shown to be a weak immunogen; infrequent, mild,localized and self-limiting), intimal peel formation, and conduit dilatation, any of which could lead to re-operation, explantation, permanent disability, and death.
CAUTION: US law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information.
PP-US--4852